Search

Displaying results 6201 - 6210 of 10000 in total
  1. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind

  2. Drug

    Mepartricin

    go.drugbank.com/drugs/DB13633
    Investigational

    Categories: Drugs Used in Benign Prostatic Hypertrophy
  3. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  4. Drug

    Zeranol

    go.drugbank.com/drugs/DB11478
    ExperimentalVet approved

    It is a mycotoxin, derived from fungi in the Fusarium family, and may be found as a contaminant in fungus-infected crops. … It is 3-4x more potent as an estrogen agonist than the related compound zearalenone.

  5. Drug

    Prolectin-M

    go.drugbank.com/drugs/DB16521
    Investigational

    [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)). … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin.

  6. Drug

    AVI-7537

    go.drugbank.com/drugs/DB15433
    Investigational

    [L46207] AVI-7537 is under investigation in clinical trial NCT01593072 (A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers). … AVI-7537 is an antisense molecule that binds to the Ebola virus mRNA to prevent the viral replication.

  7. Drug

    Human growth hormone-releasing peptide 3

    go.drugbank.com/drugs/DB19227
    Investigational

    Human growth hormone-releasing peptide 3 is under investigation in clinical trial NCT00846872 (Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance

  8. Drug

    Abarelix

    go.drugbank.com/drugs/DB00106
    ApprovedWithdrawn

    Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.

  9. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  10. Drug

    Sonepcizumab

    go.drugbank.com/drugs/DB06305
    Investigational

    Upon administration, sonepcizumab binds S1P, which may result in the inhibition of tumor angiogenesis.